HDAC inhibitors: Clinical update and mechanism-based potential von Glaser, Keith B.

Volltext

The odyssey of marine pharmaceuticals: a current pipeline perspective von Mayer, Alejandro M.S, Glaser, Keith B, Cuevas, Carmen, Jacobs, Robert S, Kem, William, Little, R. Daniel, McIntosh, J. Michael, Newman, David J, Potts, Barbara C, Shuster, Dale E

Volltext

A renaissance in marine pharmacology: From preclinical curiosity to clinical reality von Glaser, Keith B., Mayer, Alejandro M.S.

Volltext

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation von Guo, Jun, Lam, Lloyd T., Longenecker, Kenton L., Bui, Mai H., Idler, Kenneth B., Glaser, Keith B., Wilsbacher, Julie L., Tse, Chris, Pappano, William N., Huang, Tzu-Hsuan

Volltext

Identification of VEGF Signaling Inhibition-Induced Glomerular Injury in Rats through Site-Specific Urinary Biomarkers von Yang, Yi, Kowalkowski, Kenneth, Ciurlionis, Rita, Buck, Wayne R., Glaser, Keith B., Albert, Daniel H., Blomme, Eric A. G.

Volltext

Corrigendum to “Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review” [Pharmacol. Res. 177 (2022) 106076] von Wainwright, Cherry L., Teixeira, Mauro M., Adelson, David L., Buenz, Eric J., David, Bruno, Glaser, Keith B., Harata-Lee, Yuka, Howes, Melanie-Jayne R., Izzo, Angelo A., Maffia, Pasquale, Mayer, Alejandro M.S., Mazars, Claire, Newman, David J., Lughadha, Eimear Nic, Pimenta, Adriano M.C., Parra, John A.A., Qu, Zhipeng, Shen, Hanyuan, Spedding, Michael, Wolfender, Jean-Luc

Volltext

JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL von Guo, Jun, Roberts, Lisa, Chen, Zhui, Merta, Philip J, Glaser, Keith B, Shah, O Jameel

Volltext

G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells von Cheriyath, Venugopalan, Glaser, Keith B, Waring, Jeffrey F, Baz, Rachid, Hussein, Mohamad A, Borden, Ernest C

Volltext

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor von Albert, Daniel H, Tapang, Paul, Magoc, Terrance J, Pease, Lori J, Reuter, David R, Wei, Ru-Qi, Li, Junling, Guo, Jun, Bousquet, Peter F, Ghoreishi-Haack, Nayereh S, Wang, Baole, Bukofzer, Gail T, Wang, Yi-Chun, Stavropoulos, Jason A, Hartandi, Kresna, Niquette, Amanda L, Soni, Nirupama, Johnson, Eric F, McCall, J Owen, Bouska, Jennifer J, Luo, Yanping, Donawho, Cherrie K, Dai, Yujia, Marcotte, Patrick A, Glaser, Keith B, Michaelides, Michael R, Davidsen, Steven K

Volltext

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA von Glaser, Keith B, Li, Junling, Staver, Michael J, Wei, Ru-Qi, Albert, Daniel H, Davidsen, Steven K

Volltext

Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization von Shah, O. Jameel, Lin, Xiaoyu, Li, Leiming, Huang, Xiaoli, Li, Junling, Anderson, Mark G., Tang, Hua, Rodriguez, Luis E., Warder, Scott E., McLoughlin, Shaun, Chen, Jun, Palma, Joann, Glaser, Keith B., Donawho, Cherrie K., Fesik, Stephen W., Shen, Yu, Hunter, Tony

Volltext

Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases von McClellan, William J., Dai, Yujia, Abad-Zapatero, Cele, Albert, Daniel H., Bouska, Jennifer J., Glaser, Keith B., Magoc, Terry J., Marcotte, Patrick A., Osterling, Donald J., Stewart, Kent D., Davidsen, Steven K., Michaelides, Michael R.

Volltext

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia von Shankar, Deepa B., Li, Junling, Tapang, Paul, Owen McCall, J., Pease, Lori J., Dai, Yujia, Wei, Ru-Qi, Albert, Daniel H., Bouska, Jennifer J., Osterling, Donald J., Guo, Jun, Marcotte, Patrick A., Johnson, Eric F., Soni, Niru, Hartandi, Kresna, Michaelides, Michael R., Davidsen, Steven K., Priceman, Saul J., Chang, Jenny C., Rhodes, Katrin, Shah, Neil, Moore, Theodore B., Sakamoto, Kathleen M., Glaser, Keith B.

Volltext

1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinas... von Chen, Zehan, Gopalakrishnan, Sujatha M, Bui, Mai-Ha, Soni, Niru B, Warrior, Usha, Johnson, Eric F, Donnelly, Jennifer B, Glaser, Keith B

Volltext

Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review von Wainwright, Cherry L., Teixeira, Mauro M., Adelson, David L., Braga, Fernão C., Buenz, Eric J., Campana, Priscilla R.V., David, Bruno, Glaser, Keith B., Harata-Lee, Yuka, Howes, Melanie-Jayne R., Izzo, Angelo A., Maffia, Pasquale, Mayer, Alejandro M.S., Mazars, Claire, Newman, David J., Nic Lughadha, Eimear, Pádua, Rodrigo M., Pimenta, Adriano M.C., Parra, John A.A., Qu, Zhipeng, Shen, Hanyuan, Spedding, Michael, Wolfender, Jean-Luc

Volltext

Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors von Guo, Jun, Marcotte, Patrick A, McCall, J Owen, Dai, Yujia, Pease, Lori J, Michaelides, Michael R, Davidsen, Steven K, Glaser, Keith B

Volltext

The 2021 Marine Pharmacology and Pharmaceuticals Pipeline von Wu, Alex C., Jelielek, Karolina K., Le, Henry Q., Butt, Maryam, Newman, David J., Glaser, Keith B., Pierce, Marsha L., Mayer, Alejandro M.

Volltext

Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors von Dai, Yujia, Hartandi, Kresna, Soni, Niru B., Pease, Lori J., Reuter, David R., Olson, Amanda M., Osterling, Donald J., Doktor, Stella Z., Albert, Daniel H., Bouska, Jennifer J., Glaser, Keith B., Marcotte, Patrick A., Stewart, Kent D., Davidsen, Steven K., Michaelides, Michael R.

Volltext

Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors von Ji, Zhiqin, Dai, Yujia, Abad-Zapatero, Cele, Albert, Daniel H., Bouska, Jennifer J., Glaser, Keith B., Marcotte, Patrick A., Soni, Nirupama B., Magoc, Terry J., Stewart, Kent D., Wei, Ru-Qi, Davidsen, Steve K., Michaelides, Michael R.

Volltext

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML von Zhou, Jianbiao, Bi, Chonglei, Janakakumara, Jasinghe V., Liu, Shaw-Cheng, Chng, Wee-Joo, Tay, Kian-Ghee, Poon, Lai-Fong, Xie, Zhigang, Palaniyandi, Senthilnathan, Yu, Hanry, Glaser, Keith B., Albert, Daniel H., Davidsen, Steven K., Chen, Chien-Shing

Volltext